Predicting outcomes in pulmonary arterial hypertension based on the 6-minute walk distance

Journal of Heart and Lung Transplantation

Volumn 34, Issue 3, 2015, Pages 362-368

  Farber, Harrison W ^a   Miller, Dave P ^b   McGoon, Michael D ^c,f   Frost, Adaani E ^d   Benton, Wade W ^e   Benza, Raymond L ^f  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ICON CLINICAL RESEARCH   (United States)

^c MAYO CLINIC   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e Actelion Pharmaceuticals US Inc   (United States)

^f ALLEGHENY GENERAL HOSPITAL   (United States)

Author keywords

6 minute walk distance; prognostic value; pulmonary arterial hypertension; surrogate end points; survival outcomes

Indexed keywords

ADULT; ARTICLE; EXERCISE TOLERANCE; FEMALE; FOLLOW UP; HUMAN; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; SIX MINUTE WALK DISTANCE; SURVIVAL RATE; CLINICAL TRIAL; DISEASE COURSE; EPIDEMIOLOGY; EXERCISE TEST; HYPERTENSION, PULMONARY; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; REGISTER; TIME; UNITED STATES; WALKING;

DISEASE PROGRESSION; EXERCISE TEST; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REGISTRIES; TIME FACTORS; UNITED STATES; WALKING;

EID: 84925296872     PISSN: 10532498     EISSN: 15573117     Source Type: Journal    
DOI: 10.1016/j.healun.2014.08.020     Document Type: Article

References (21)

1. R.J. Butland, J. Pang, E.R. Gross, A.A. Woodcock, and D.M. Geddes Two-, six-, and 12-minute walking tests in respiratory disease Br Med J (Clin Res Ed) 284 1982 1607 1608
2. R. Temple Are surrogate markers adequate to assess cardiovascular disease drugs? JAMA 282 1999 790 795
3. V.V. McLaughlin, D.B. Badesch, and M. Delcroix End points and clinical trial design in pulmonary arterial hypertension J Am Coll Cardiol 54 2009 S97 107
4. D.B. Taichman, J. Shin, and L. Hud Health-related quality of life in patients with pulmonary arterial hypertension Respir Res 6 2005 92
5. T.R. Fleming, and J.H. Powers Biomarkers and surrogate endpoints in clinical trials Stat Med 31 2012 2973 2984
6. R.L. Benza, D.P. Miller, and M. Gomberg-Maitland Predicting survival in pulmonary arterial hypertension: Insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management (REVEAL) Circulation 122 2010 164 172
7. M. Humbert, O. Sitbon, and A. Chaouat Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era Circulation 122 2010 156 163
8. S. Miyamoto, N. Nagaya, and T. Satoh Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing Am J Respir Crit Care Med 161 2000 487 492
9. N. Nickel, H. Golpon, and M. Greer The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension Eur Respir J 39 2012 589 596
10. J.S. Fritz, C. Blair, and R.J. Oudiz Baseline and follow-up 6-min walk distance and brain natriuretic peptide predict 2-year mortality in pulmonary arterial hypertension Chest 143 2013 315 323
11. A. Macchia, R. Marchioli, and R. Marfisi A meta-analysis of trials of pulmonary hypertension: A clinical condition looking for drugs and research methodology Am Heart J 153 2007 1037 1047
12. O. Sitbon, M. Humbert, and H. Nunes Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival J Am Coll Cardiol 40 2002 780 788
13. P.L. Enright, and D.L. Sherrill Reference equations for the six-minute walk in healthy adults Am J Respir Crit Care Med 158 1998 1384 1387
14. W.T. Lee, A.J. Peacock, and M.K. Johnson The role of per cent predicted 6-min walk distance in pulmonary arterial hypertension Eur Respir J 36 2010 1294 1301
15. H.W. Farber Validation of the 6-minute walk in patients with pulmonary arterial hypertension: trying to fit a square peg into a round hole? Circulation 126 2012 258 260
16. N.B. Gabler, B. French, and B.L. Strom Validation of 6-minute walk distance as a surrogate end point in pulmonary arterial hypertension trials Circulation 126 2012 349 356
17. M.D. McGoon, A. Krichman, and H.W. Farber Design of the reveal registry for us patients with pulmonary arterial hypertension Mayo Clin Proc 83 2008 923 931
18. G. Simonneau, N. Galie, and L.J. Rubin Clinical classification of pulmonary hypertension J Am Coll Cardiol 43 2004 5 12S
19. R.L. Benza, M. Gomberg-Maitland, and D.P. Miller The REVEAL registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension Chest 141 2012 354 362
20. A.E. Frost, D.B. Badesch, D.P. Miller, R.L. Benza, L.A. Meltzer, and M.D. McGoon Evaluation of the predictive value of a clinical worsening definition using 2-year outcomes in patients with pulmonary arterial hypertension: a REVEAL registry analysis Chest 144 2013 1521 1529
21. N.R. Cook Use and misuse of the receiver operating characteristic curve in risk prediction Circulation 115 2007 928 935